Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.

Diabetes technology & therapeutics

Volumn 1, Issue 3, 1999, Pages 247-256

  Strange, P ^a   Schwartz, S L ^a   Graf, R J ^a   Polvino, W ^a   Weston, I ^a   Marbury, T C ^a   Huang, W C ^a   Goldberg, R B ^a  

^a NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; INSULIN; PIPERIDINE DERIVATIVE; PLACEBO; REPAGLINIDE;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ETHNIC GROUP; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADULT; BLOOD GLUCOSE; CARBAMATES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETHNIC GROUPS; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PIPERIDINES; PLACEBOS; UNITED STATES;

EID: 0033188523     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/152091599317143     Document Type: Article

References (0)